<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193892</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC091502LAM</org_study_id>
    <nct_id>NCT03193892</nct_id>
  </id_info>
  <brief_title>A National Registry on Chinese Patients With Lymphangioleiomyomatosis</brief_title>
  <official_title>A National Registry on Clinical Manifestations, Genetics, Interventions, and Outcomes in Chinese Patients With Lymphangioleiomyomatosis (LAM-CHINA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Institute of Respiratory Disease</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuxi People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Shijitan Hospital, Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan TongJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes&#xD;
      in the lung, is a rare disorder that affects almost exclusively women. The main objectives of&#xD;
      this study are to accurately evaluate the prevalence of LAM, the status of disease, the&#xD;
      diagnosis and treatment, the quality of care, and the health related outcomes in China.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes&#xD;
      in the lung, is a rare disorder that affects almost exclusively women. The main objectives of&#xD;
      this study are to accurately evaluate the prevalence of LAM, the status of disease, the&#xD;
      diagnosis and treatment, the quality of care, and the health related outcomes in China. This&#xD;
      is a register study lasting 4 years, aims to raise 800 subjects. Primary endpoint is the&#xD;
      annual change of forced expiratory volume in the first second (FEV1) and forced vital&#xD;
      capacity (FVC) in pulmonary function tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Change in spirometry (FEV1 and FVC) of lymphangioleiomyomatosis patients.</measure>
    <time_frame>10 years</time_frame>
    <description>Spirometry will be evaluated at baseline and through study completion, an average of 3 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of diffusing capacity of the lung.</measure>
    <time_frame>10 years</time_frame>
    <description>Pulmonary function tests will be evaluated at baseline and through study completion, an average of 3 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual incidence of major health outcomes: hemoptysis, pneumothorax, chylothorax, and spontaneous hemorrhage of kidney angiomyolipoma (AML).</measure>
    <time_frame>10 years</time_frame>
    <description>The number of occurrences will be recorded through study completion, an average of 3 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other health outcomes: pregnancy, malignant tumors except LAM, lung transplantation, and death.</measure>
    <time_frame>10 year</time_frame>
    <description>The number of occurrences will be recorded through study completion, an average of 3 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse drug reactions of long-time treatment with rapamycin.</measure>
    <time_frame>10 years</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) will be used to evaluate adverse drug reactions through study completion, an average of 3 years.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Pulmonary Function</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biological specimens are preserved in serum, plasma, and leukocytes&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study Population is from across the country of China.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Gender: female.&#xD;
&#xD;
          2. Age: no limitation.&#xD;
&#xD;
          3. Diagnosis meets one of the following criteria, (1) definite or probable diagnosis of&#xD;
             LAM based on ATS/JRS and ERS criteria. (2) Investigators recommend including of the&#xD;
             patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Suspected LAM patients without other supporting evidence for LAM diagnosis.&#xD;
&#xD;
          2. No diffuse cystic lesions in the lung.&#xD;
&#xD;
          3. Patients with bilateral cystic lung lesions but the LAM diagnosis cannot be&#xD;
             established.&#xD;
&#xD;
          4. Without signed informed consent.&#xD;
&#xD;
          5. Difficult to follow up.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pulmonary lymphangioleiomyomatosis (LAM) affects almost exclusively women.</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kai-Feng Xu, M.D.</last_name>
    <phone>86-10-69155039</phone>
    <email>xukf@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai-Feng Xu, M.D.</last_name>
      <phone>86-10-69155039</phone>
      <email>xukf@pumch.cn</email>
    </contact>
    <contact_backup>
      <last_name>XinLun Tian, M.D.</last_name>
      <phone>86-10-69155039</phone>
      <email>xinlun_t@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xinlun Tian, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kai-Feng Xu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>registry</keyword>
  <keyword>China</keyword>
  <keyword>lymphangioleiomyomatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphangioleiomyomatosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Currently, there is no such a plan to share IPD to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

